Efficient Elimination of Cells from Patients with Different AML Subtypes by Dual-Targeting Triplebody 33-16-123

被引：0
|
作者：
Braciak, T. [1 ]
Fenn, N. [2 ,3 ]
Wildenhain, S. [2 ,3 ]
Schiller, C. [1 ,2 ,3 ]
Roskopf, C.
Schubert, I. [4 ]
Jacob, U. [5 ]
Hopfner, K. P. [2 ,3 ]
Honegger, A. [6 ]
Aigner, M. [7 ]
Krause, S. [7 ]
Macken-sen, A. [7 ]
Subklewe, M. [1 ,8 ]
Krupka, C. [1 ,8 ]
Spiekermann, K. [1 ]
Fey, G. [4 ]
Oduncu, F. S. [1 ]
机构：
[1] Klinikum Univ Munchen, Med Klin & Poliklin 3, Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Dept Biochem, Munich, Germany
[3] Ludwig Maximilians Univ Munchen, Gene Ctr, Munich, Germany
[4] Univ Erlangen Nurnberg, Dept Biol, Erlangen, Germany
[5] Westend Innovat, Munich, Germany
[6] Univ Zurich, Dept Biochem, Zurich, Switzerland
[7] Univ Erlangen Nurnberg, Dept Internal Med 5, Erlangen, Germany
[8] Ludwig Maximilians Univ Munchen, Lab Translat Canc Immunol, Gene Ctr, Munich, Germany
来源：
ANNALS OF HEMATOLOGY | 2019年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
69
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 14 条
  • [1] Elimination of Cells from Patients with Different Subtypes of AML by Dual-Targeting Triplebody 33-16-123 (SPM-2)
    Braciak, T.
    Fenn, N.
    Wildenhain, S.
    Schiller, C.
    Roskopf, C.
    Schubert, I.
    Jacob, U.
    Hopfner, K. P.
    Aigner, M.
    Mackensen, A.
    Subklewe, M.
    Spiekermann, K.
    Fey, G. H.
    Oduncu, F.
    ANNALS OF HEMATOLOGY, 2017, 96 : S81 - S81
  • [2] Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
    Braciak, Todd A.
    Roskopf, Claudia C.
    Wildenhain, Sarah
    Fenn, Nadja C.
    Schiller, Christian B.
    Schubert, Ingo A.
    Jacob, Uwe
    Honegger, Annemarie
    Krupka, Christina
    Subklewe, Marion
    Spiekermann, Karsten
    Hopfner, Karl-Peter
    Fey, Georg H.
    Aigner, Michael
    Krause, Stefan
    Mackensen, Andreas
    Oduncu, Fuat S.
    ONCOIMMUNOLOGY, 2018, 7 (09):
  • [3] SELECTIVE LYSIS OF BIPHENOTYPIC LEUKAEMIA CELLS IS MEDIATED BY DUAL-TARGETING TRIPLEBODY 33-3-19 TREATMENT
    Claudia, Roskopf C.
    Todd, Braciak A.
    Nadja, Fenn
    Sebastian, Kobold
    Uwe, Jacob
    Georg, Fey H.
    Karl-Peter, Hopfner
    Fuat, Oduncu S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S9 - S9
  • [4] Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cells
    Roskopf, Claudia C.
    Braciak, Todd A.
    Fenn, Nadja C.
    Kobold, Sebastian
    Fey, Georg H.
    Hopfner, Karl-Peter
    Oduncu, Fuat S.
    ONCOTARGET, 2016, 7 (16) : 22579 - 22589
  • [5] Dual-Targeting CD33/CD123 NANOBODY ® T Cell Engager Targeting Leukemia Blasts and Stem/Progenitor Cells in Relapsed AML
    Zeng, Zhihong
    Roobrouck, Annelies
    Deschamps, Geert
    Bonnevaux, Helene
    Guerif, Stephane
    De Brabandere, Veronique
    Celine, Amara
    Jonckheere, Eline
    Virone-Oddos, Angela
    Chiron, Marielle
    Dullaers, Melissa
    Konopleva, Marina Y.
    BLOOD, 2023, 142
  • [6] A TRISPECIFIC ANTIBODY DERIVATIVE DIRECTED AGAINST CD123 AND CD33 MEDIATES EFFECTIVE ELIMINATION OF AML CELLS BY DUAL TARGETING
    Kuegler, Markus
    Stein, Christoph
    Kellner, Christian
    Mentz, Kristin
    Saul, Domenica
    Schwenkert, Michael
    Schubert, Ingo
    Singer, Heiko
    Oduncu, Fuat
    Stockmeyer, Bernhard
    Mackensen, Andreas
    Hillen, Wolfgang
    Fey, Georg H.
    ANNALS OF HEMATOLOGY, 2011, 90 : S1 - S1
  • [7] POTENT LYSIS OF AML BLASTS BY TRILYTE SPM-2 WITH DUAL-TARGETING OF CD33 AND CD123 IN COMBINATION WITH SUBSETS OF NK CELLS
    Maier, C. P.
    Heubach, F.
    Herrmann, S.
    Kuemmerle, P.
    Braciak, T. A.
    Fenn, N.
    Schele, A.
    Schubert, I.
    Hopfner, K. P.
    Krupka, C.
    Subklewe, M.
    Aigner, M.
    Mackensen, A.
    Lengerke, C.
    Fey, G. H.
    Peipp, M.
    Lang, P.
    Oduncu, F.
    ANNALS OF HEMATOLOGY, 2023, 102 (SUPPL 1) : S65 - S65
  • [8] Effective lysis of MOLM-13 and AML blasts by triplebody spm-2 (cd123-16-33) in combination with subsets of nk cells
    Maier, C-P.
    Heubach, F.
    Herrmann, S.
    Kummerle, P.
    Arendt, A-M.
    Rabsteyn, A.
    Fey, G. H.
    Peipp, M.
    Lengerke, C.
    Bethge, W.
    Handgretinger, R.
    Lang, P.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 336 - 337
  • [9] Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile
    Zeng, Zhihong
    Roobrouck, Annelies
    Deschamps, Geert
    Bonnevaux, Helene
    Guerif, Stephane
    De Brabandere, Veronique
    Amara, Celine
    Dejonckheere, Eline
    Virone-Oddos, Angela
    Chiron, Marielle
    Konopleva, Marina
    Dullaers, Melissa
    BLOOD ADVANCES, 2024, 8 (09) : 2059 - 2073
  • [10] Improved Killing of AML Blasts By Dual-Targeting of CD123 and CD33 Via Unitarg a Novel Antibody-Based Modular T Cell Retargeting System
    Arndt, Claudia
    Feldmann, Anja
    Koristka, Stefanie
    Cartellieri, Marc
    von Bonin, Malte
    Ehninger, Armin
    Bornhaeuser, Martin
    Ehninger, Gerhard
    Bachmann, Michael P.
    BLOOD, 2015, 126 (23)
12